Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2025 Results presented in the Neurolixis Media Release.
18 Mar 2025 According to a Neurolixis media release, company announced the publication of the results from its successful Phase 2A proof-of-concept clinical trial of NLX-112 in the journal Movement Disorders.
15 Jan 2024 According to a Neurolixis media release, results of this study were discussed in a new interview between Arthur Roach, director of Parkinson's UK Virtual Biotech, and Adrian Newman-Tancredi, CEO of Neurolixis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com